“…(Von der Weid,2001; Langer et al,2002; Hill et al,2004; Spiegler et al,2006; Mahone et al,2007; Aukema et al,2009; Kadan-Lottick et al,2009; Kadan-Lottick et al,2010; Robinson et al,2010; Daams et al,2012; Krawczuk-Rybak et al,2012; Edelmann et al,2013; Genschaft et al,2013; Krull et al,2013; Lewis et al,2013; Ross et al,2013; Schuitema et al,2013; Edelmann et al,2014; Elalfy et al,2014) There were only 4 longitudinal studies that evaluated survivors’ neurocognitive changes from active treatment to post-treatment survivorship phase. (Kingma et al,2001; Harila et al,2009; Halsey et al,2011; Lewis et al,2013) Most studies focused on a pure sample of survivors who received chemotherapy-only treatment protocols while others included separate populations of ALL survivors who received CRT(Kingma et al,2001; Von der Weid,2001; Langer et al,2002; Spiegler et al,2006; Harila et al,2009; Kadan-Lottick et al,2010; Halsey et al,2011; Krull et al,2011; Daams et al,2012; Krull et al,2013; Schuitema et al,2013; Edelmann et al,2014) or patients of other cancer types.…”